Skip to content

Spread of drug-resistant virus remains stable during expanded drug access in Côte d’Ivoire

Avoid d4T say investigators after finding high incidence of lactic acidosis in Botswana

Two and a half years extra ART if treatment starts at 500 CD4s, not 350

Defining, and then watching for, treatment failure

EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance

EACS: Nevirapine studies highlight new first-line uses

EACS: Kaletra monotherapy may need excellent adherence to work

EACS: Growth-hormone drug reduces abdominal fat – if you keep on taking it

EACS: CD4 cells: the lower you start, the lower you finish